Recombinant Human Ret His-tag Protein, CF

When Recombinant Human Ret His-tag (Catalog # 10302-CR) is immobilized at 1 μg/mL, 100 μL/well, Recombinant Human GDNF (Catalog # 212-GD) binds with an ED50 of 0.03‑0.3 μg/mL in the presence of Recombinant Human GFR alpha-1 Fc Chimera (Catalog # 714-GR).

2 μg/lane of Recombinant Human Ret His-tag (Catalog # 10302-CR) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 101-113 kDa.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human Ret His-tag Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human Ret His-tag (Catalog # 10302-CR) is immobilized at 1 µg/mL (100 µL/well), Recombinant Human GDNF (Catalog # 212-GD) binds with an ED₅₀ of 0.03-0.3 μg/mL in the presence of Recombinant Human GFR alpha ‑1/GDNF R alpha‑1 Fc Chimera (Catalog # 714-GR).
• Source: Mouse myeloma cell line, NS0-derived human Ret protein
  Leu29-Arg635, with a C-terminal 10-His tag
• Accession #: P07949
• N-terminal Sequence: Leu29
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 69 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 101-113 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Ret His-tag Protein, CF

• CDHF12MTC1
• CDHR16
• EC 2.7.10
• Hirschsprung disease 1
• Hirschsprung disease)
• MEN2A
• MEN2B
• multiple endocrine neoplasia and medullary thyroid carcinoma 1
• ret proto-oncogene
• RET transforming sequence
• Ret

Background

Receptor tyrosine-protein kinase, also known as Ret, is encoded by the C-RET proto-oncogene. Mutations of the C-RET gene have been associated with various human diseases affecting tissues derived from the neural crest, including Hirschsprung's disease, multiple endocrine neoplasia MEN2A and MEN2B, and familial medullary thyroid carcinoma (1, 2, 3). Human C-RET cDNA encodes a 1115 amino acid (aa) with a 28 aa signal peptide, a 679 aa cysteine-rich extracellular domain that contains an membrane anchored Ret-Cadherin 120 Da fragment, and a 456 aa rcytoplasmic domain with a soluble Ret kinase fragment (4). Human and mouse Ret share 83% amino acid sequence homology (77% homology in the extracellular domain and 93% homology in the cytoplasmic domain). Although Ret does not bind GDNF ligands directly, the extracellular domain of Ret binds the GDNF-GFR-alpha complex with high affinity and is a potent GDNF antagonist in the presence of soluble GFR-alpha (5).

1. Ma, Q. (2009) Neuron 64:773.
2. Carlomagno, F. et al. (1998) Endocrinology 139:3613.
3. Cabrera, J.R. et al. (2011) J. Biol. Chem. 286:14628.
4. Iwamoto, T. et al. (1993) Oncogene 8:1087.
5. Yang, L. et al. (2017) Nat. Med. 23:1158.

Bioinformatics

• Uniprot:
  • P07949()